AI-based life sciences discovery and development company Matterworks has introduced its new AI-driven platform, Pyxis, designed to simplify and enhance the quantification of "analytes," which are chemical substances related to the analytical stage of a drug's discovery process.

According to the company, the platform can standardize the whole quantitation process of untargeted analytes, which is typically a complex procedure. It eliminates the need for per-analyte calibration, peak selection, integration, and manual data analysis, and enables direct conversion of raw LC-MS data into a list of detected metabolites with their respective concentrations, which is biologically actionable. 

Matterworks develops advanced AI platforms for modeling real-time biology, accelerating the discovery, development, and manufacturing of life sciences technologies. The company's key offering is Pyxis, an ML software that revolutionizes metabolomics workflows by compressing weeks of traditional data acquisition and interpretation into real-time insight generation.